Targeted Oncology2d
FDA Fast-Tracks IBI363 in Squamous NSCLC
The FDA granted fast track status to IBI363 for the treatment of patients with advanced squamous lung cancer after prior ...
Lung cancer rising among non-smokers — here's why
The most common form of lung cancer is primarily found in non-smokers, a new study reveals. Doctors react to the surprising ...
Discover Magazine6d
There's a Growing Number of Lung Cancer Cases From People Who’ve Never Smoked
Air pollution might be playing an increasing role in causing the disease.
Pharmabiz2d
Innovent receives second fast track designation from US FDA for IBI363 in squamous non-small cell lung cancer
San Francisco, US Tuesday, February 18, 2025, 09:00 Hrs [IST] ...
Targeted Oncology3d
Brahmer Considers First-Line Immunotherapy Options in Metastatic NSCLC
During a Case-Based Roundtable® event, Julie R. Brahmer, MD, MSC, reviewed the CheckMate 9LA, KEYNOTE-407, and POSEIDON ...
Boehringer’s zongertinib receives Priority Review from U.S. FDA for the treatment of HER2 (ERBB2)-mutant advanced non-small cell lung cancer
Ridgefield, Conn., U.S., and Ingelheim, GermanyZongertinib would be the first orally administered, targeted therapy for previously treated ...
Managed Healthcare Executive3d
Cost-Effectiveness Study: Libtayo “More Favorable” Than Keytruda for First-Line Treatment of Advanced NSCLC
Study shows that Libtayo plus chemotherapy has lower cost and a larger effect on improving quality-adjusted life years than ...
Healio3d
High prevalence of atherosclerosis detected in patients entering lung cancer therapy
CT imaging of patients entering lung cancer treatment identified a high prevalence of atherosclerosis, according to data ...
BioSpace6d
Amgen, Ideaya Call It Quits on Cancer Combo
Amgen will continue to advance half of the combo, PRMT5 inhibitor AMG 193, for which it is running a mid-stage trial in ...
Medscape8d
Immunotherapy Reduces Skin Cancer Precursors
A new pilot cohort study linked immune checkpoint inhibitors with a reduction in actinic keratoses in patients undergoing ...
Monthly Prescribing Reference1d
Zongertinib Under Review for HER2-Mutant Advanced NSCLC
The Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application for zongertinib for the treatment of adult patients with ...